Ignite Creation Date:
2024-05-06 @ 10:27 AM
Last Modification Date:
2024-10-26 @ 12:30 PM
Study NCT ID:
NCT03268954
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-30
First Post:
2017-08-30
Brief Title:
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes HR MDS Chronic Myelomonocytic Leukemia CMML or Low-Blast Acute Myelogenous Leukemia AML
Sponsor:
Organization:
Takeda